针对CDK12的抗癌药物的研究进展
Zhijia Yan1, Yongli Du1, Haibin Zhang1
1School of Chemistry & Chemical Engineering, Qilu University of Technology (Shandong Academy of Sciences) 3501 Da Xue Road Jinan 250353 China yldu2016@163.com.
循环素依赖激酶12 (CDK12) 对于细胞功能至关重要,并与多种癌症有关. 抑制CDK12显示出作为癌症治疗的希望,尽管在开发选择性抑制剂方面存在挑战.
科学领域:
- 分子生物学分子生物学
- 在瘤学瘤学.
- 药物发现 药物发现 药物发现
背景情况:
- 环林依赖激酶12 (CDK12) 是转录,翻译,mRNA剪接,细胞周期和DNA修复的关键调节者.
- 增加的CDK12表达与HER2阳性乳腺癌,胃癌和宫癌有关.
- 抑制CDK12抑制瘤生长,将其定位为癌症生物标志物和治疗点.
研究的目的:
- 审查目前对循环素依赖性激酶12 (CDK12) 抑制剂的研究.
- 阐明CDK12抑制剂的作用机制和结构-活性关系.
- 为设计选择性CDK12抑制剂提供见解.
主要方法:
- 对CDK12抑制剂研究的文献综述.
- 对CDK12在癌症发病过程中的作用的分析.
- 检查抑制剂结合机制和结构-活性关系.
主要成果:
- CDK12抑制剂通过竞争性结合CDK12的ATP结合口袋来起作用,防止酸化和下游信号传递.
- CDK12和其他循环林依赖性激酶之间的高同质性对开发选择性抑制剂提出了挑战.
- 结构-活性关系研究对于理解抑制剂的有效性和选择性至关重要.
结论:
- CDK12是各种癌症的有希望的治疗点.
- 选择性CDK12抑制剂的开发需要仔细考虑结构同质性.
- 对CDK12抑制剂的进一步研究可能会导致新的癌症治疗方法.
更多相关视频
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
相关概念视频
Inhibition of Cdk Activity
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Positive Regulator Molecules
